** Shares of drugmaker Aurinia Pharmaceuticals AUPH.O rise 6.38% to $8 premarket
** Co says it is implementing a strategic restructuring to focus on its lupus nephritis treatment Lupkynis and the development of AUR200, which is in early stage study
** The restructuring will result in a workforce reduction of about 45%
** AUPH anticipates a one-time restructuring charge in Q4 of $15 mln to $19 mln
** Estimates post-restructuring annualized cash-based operating expense savings of more than $40 million
** Reiterates 2024 net product revenue forecast range of $210 to $220 million
** Up to last close, stock down ~16% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.